Search
for
Sort by
Research 991–1000 of 1000+
- Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
- Supplemental Figure 1 for "Time to Maximal Response with Low-Dose Oral Minoxidil in Clinical Treatment of Androgenetic Alopecia"
- Supplemental Figure 1 for "Time to Maximal Response with Low-Dose Oral Minoxidil in Clinical Treatment of Androgenetic Alopecia"
- Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial
- Supplementary Materials for Safety and tolerability of combination oral spironolactone and low-dose oral minoxidil for hair loss in adult females: A retrospective cohort study
- Supplementary Materials for Safety and tolerability of combination oral spironolactone and low-dose oral minoxidil for hair loss in adult females: A retrospective cohort study
- Comparative Evaluation of the Efficacy and Safety of Oral Finasteride versus Oral Dutasteride in Male Androgenetic Alopecia: An 18-Month Prospective Interventional Study from a Tertiary Care Centre in Uttar Pradesh
- Signal Mining for Non-Bleeding Adverse Event in Novel Oral Anticoagulants: A Pharmacovigilance Study Based on the FAERS Database
- BH19 ‘JAK in the box?’ Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata
- P075 A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata